Today, as Member States adopt resolution EB144.R11 on antimicrobial resistance recommended by the WHO’s Executive Board at the World Health Assembly, GARDP has issued the following response:
Dr Manica Balasegaram, Executive Director, GARDP said:
GARDP welcomes the adoption of today’s resolution on AMR.
We need urgent collective action to tackle AMR. WHO has signalled its commitment with the creation of an ADG and Department for AMR but all stakeholders have a critical role to play, including countries, the Tripartite Plus and donors.
For our part, GARDP is redoubling its efforts, currently focused on developing antibiotics to treat children, neonates with sepsis and sexually transmitted infections, while integrating strategies for sustainable access. Later this year we will launch an ambitious new strategy with expanded priorities.
Continued political commitment at the highest level is necessary including at the UN High-Level Meeting on Universal Health Coverage at the UN General Assembly in September.
GARDP is a not-for-profit research and development organization that addresses global public health needs by developing and delivering new or improved antibiotic treatments, while endeavouring to ensure their sustainable access. Initiated by the WHO and the Drugs for Neglected Disease initiative (DNDi), GARDP is an important element of WHO’s Global Action Plan on Antimicrobial Resistance that calls for new public-private partnerships to encourage research and development of new antimicrobial agents and diagnostics.
Read GARDP’s full intervention